On 12th July 2026, Indian healthcare entrepreneur GSK Velu is preparing for a major milestone in his business journey by planning to list four of his healthcare companies on the stock market over the next three years. The move is expected to unlock significant value across his healthcare portfolio and strengthen the businesses for their next stage of growth.
Together, these companies generate annual revenues of more than ₹7,000 crore and operate across medical technology, diagnostics, eye care, and hospital services. The planned public listings are expected to attract strong investor interest as India's healthcare sector continues to expand. According to Velu, the strategy will help each business raise fresh capital, accelerate expansion, and improve its long-term market position.
“Neuberg and Maxivision are expected to go public first, possibly in 2027, followed by Kauvery. Trivitron could list after a major acquisition and another private equity round,” Velu told Fortune India in an exclusive interview.
Trivitron expects its revenue to touch ₹1,000 crore in FY27 and aims to triple its turnover over the next five years, Velu said.
As of now, there are around 250 Neuberg laboratories across India. In 2025, the company generated a revenue of approximately ₹1,600-1,700 crore, and it is expected that in FY27, the company may achieve a revenue target of around ₹2,000.
The four companies identified for listing are Trivitron Healthcare, Neuberg Diagnostics, Maxi Vision Eye Hospitals, and Kauvery Hospitals. Each business serves a different part of the healthcare industry and has built a strong presence over the years. Neuberg Diagnostics operates pathology laboratories and diagnostic services across India and international markets. Maxi Vision has grown into a leading network of eye care hospitals. Kauvery Hospitals has expanded into a respected multi-specialty hospital chain, while Trivitron Healthcare manufactures medical devices and diagnostic equipment used by hospitals and laboratories. By listing these businesses separately, Velu believes each company can pursue its own growth strategy while creating greater value for shareholders. Industry experts estimate that the combined market value of these businesses could exceed four billion dollars once they are publicly listed.
Velu has outlined a phased approach for the proposed listings. Neuberg Diagnostics and Maxi Vision are expected to be the first companies to launch their initial public offerings, possibly in 2027. Kauvery Hospitals is likely to follow after that. Trivitron Healthcare may enter the stock market later because the company plans to complete a major acquisition and secure another round of private equity funding before moving ahead with its IPO. This step-by-step strategy is intended to ensure that every company reaches the market at the right stage of its growth journey. Rather than rushing multiple listings at once, the businesses will focus on strengthening operations, improving financial performance, and expanding their services before approaching public investors.
Velu has built one of India's most diversified healthcare business portfolios over the past several decades. He owns Trivitron Healthcare completely, holds around two-thirds of Neuberg Diagnostics, more than sixty percent of Maxi Vision, and over twenty percent of Kauvery Hospitals. He also owns significant stakes in Apollo Dental and Apollo Dialysis, further expanding his presence in specialized healthcare services. His businesses cover nearly every major segment of the healthcare ecosystem, from medical technology manufacturing and laboratory diagnostics to hospital care and specialty clinics. This broad presence allows the group to benefit from the increasing demand for quality healthcare services across India.
The planned IPOs also reflect the growing confidence in India's healthcare industry. Rising healthcare spending, expanding insurance coverage, greater awareness of preventive healthcare, and increasing investments in advanced medical technology have created strong growth opportunities for healthcare companies. Investors are showing greater interest in businesses that offer essential healthcare services backed by modern technology and expanding customer demand.
For Velu, taking these companies public is not only about raising funds. Public listings can improve corporate governance, increase transparency, and provide easier access to capital for future expansion. The additional funding could support new hospitals, diagnostic centres, manufacturing facilities, technology upgrades, and strategic acquisitions. It may also help these companies strengthen their presence in international markets while improving patient care through innovation and advanced medical solutions.
If the planned listings move forward as expected, they could become some of the most closely watched healthcare IPOs in India over the next few years. The move highlights the growing maturity of India's healthcare industry and demonstrates how successful healthcare entrepreneurs are preparing their businesses for the next phase of long-term growth and global competitiveness.
